Related Experiment Videos

Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism

R Miyoshi1, S Kito, H Ishida

  • 1Third Department of Internal Medicine, Hiroshima University School of Medicine, Japan.

Research Communications in Chemical Pathology and Pharmacology
|October 1, 1988
PubMed

Insights

MPTP-induced parkinsonian monkeys showed neuronal degeneration in the substantia nigra and locus coeruleus. Adrenergic receptor changes in these monkeys closely mirror those seen in human Parkinson's disease.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Pharmacology

Background:

  • Parkinson's disease is a neurodegenerative disorder affecting motor function.
  • The coeruleo-cortical adrenergic system plays a role in neurological functions.
  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin used to model parkinsonism in animals.

Purpose of the Study:

  • To investigate alterations in the coeruleo-cortical adrenergic system in MPTP-induced monkey parkinsonism.
  • To compare neuropathological and receptor binding changes in MPTP-treated monkeys with human Parkinson's disease.

Main Methods:

  • Neuropathological examination of brain tissue from MPTP-treated monkeys.
  • Radioreceptor assay to quantify adrenergic receptor levels in specific brain regions.

Main Results:

  • MPTP treatment caused neuronal degeneration in both the substantia nigra and locus coeruleus.
  • Decreased alpha 1 and alpha 2 adrenergic receptors were observed in the parietal and temporal cortices.
  • An increase in beta adrenergic receptors was noted in the temporal cortex.

Conclusions:

  • MPTP-induced monkey parkinsonism exhibits significant neuropathological changes in key brainstem nuclei.
  • Adrenergic receptor alterations in the cortex of parkinsonian monkeys resemble those found in human Parkinson's disease.
  • This model effectively replicates crucial aspects of the human disease, aiding further research.

Related Concept Videos